Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
AstraZeneca PLC ADR is a drug manufacturers-general business based in the US. AstraZeneca PLC ADR shares (AZN) are listed on the NASDAQ and all prices are listed in US Dollars. AstraZeneca PLC ADR employs 83,500 staff and has a trailing 12-month revenue of around USD$43.8 billion.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
| Latest market close | $72.52 |
|---|---|
| 52-week range | $51.90 - $76.56 |
| 50-day moving average | $72.14 |
| 200-day moving average | $65.95 |
| Wall St. target price | $79.43 |
| PE ratio | 48.245 |
| Dividend yield | $2.9 (1.95%) |
| Earnings per share (TTM) | $1.51 |
Historical closes compared with the close of $72.52 from 2023-05-26
| 1 week (2023-05-23) | -2.09% |
|---|---|
| 1 month (2023-04-28) | -0.96% |
| 3 months (2023-03-02) | 11.40% |
| 6 months (2022-11-30) | 6.69% |
| 1 year (2022-05-27) | 7.60% |
|---|---|
| 2 years (2021-05-28) | 27.74% |
| 3 years (2020-05-29) | 32.82% |
| 5 years (2018-05-30) | 96.74% |
Valuing AstraZeneca PLC ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca PLC ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $43.8 billion |
|---|---|
| Operating margin TTM | 23.1% |
| Gross profit TTM | $35.7 billion |
| Return on assets TTM | 6.43% |
| Return on equity TTM | 13.05% |
| Profit margin | 10.73% |
| Book value | $1.92 |
| Market capitalisation | $226.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 43.28% of net profits
Recently AstraZeneca PLC ADR has paid out, on average, around 43.28% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.95% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca PLC ADR shareholders could enjoy a 1.95% return on their shares, in the form of dividend payments. In AstraZeneca PLC ADR's case, that would currently equate to about $2.9 per share.
While AstraZeneca PLC ADR's payout ratio might seem fairly standard, it's worth remembering that AstraZeneca PLC ADR may be investing much of the rest of its net profits in future growth.
AstraZeneca PLC ADR's most recent dividend payout was on 27 March 2023. The latest dividend was paid out to all shareholders who bought their shares by 23 February 2023 (the "ex-dividend date").
AstraZeneca PLC ADR's shares were split on a 2:1 basis on 27 July 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca PLC ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca PLC ADR shares which in turn could have impacted AstraZeneca PLC ADR's share price.
Over the last 12 months, AstraZeneca PLC ADR's shares have ranged in value from as little as $51.8968 up to $76.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca PLC ADR's is 0.1787. This would suggest that AstraZeneca PLC ADR's shares are less volatile than average (for this exchange).
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
Find out how major crypto exchanges and brokers fared in 2023’s Global Crypto Trading Platform Awards.
This guide provides step-by-step instructions on how to buy Blur, lists some exchanges where you can get it and provides daily price data on (BLUR).
This guide provides step-by-step instructions on how to buy FLOKI Inu, lists some exchanges where you can get it and provides daily price data on (FLOKI).
This guide provides step-by-step instructions on how to buy SSV Network, lists some exchanges where you can get it and provides daily price data on (SSV).
This guide provides step-by-step instructions on how to buy Optimism, lists some exchanges where you can get it and provides daily price data on (OP).
A panel of industry specialists give us their predictions on the price of Bitcoin to 2030.
Compare share trading apps to find out which app has all the tools and resources you need to reach your investment goals.
The definitive ranking of the NFT adoption across 26 countries.
Read our expert analysis on STEPN and how the token will perform in the future.
